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Carlo A. Dall’Olmo, MD,b Sint Maarten; and Flint, Mich
Objective: Currently, no formal practice guidelines exist regarding the use of endografts to exclude hemodialysis access
pseudoaneurysms and prolong access lifespan in dialysis patients. We evaluated the efﬁcacy of percutaneous endograft
placement for exclusion of hemodialysis access pseudoaneurysms.
Methods: Between July 2005 and October 2009, 32 patients were prospectively evaluated. Twenty-four patients were
actively enrolled in the study based upon clinical and ultrasonographic evaluation of their hemodialysis accesses. Self-
expanding covered endografts were placed percutaneously to exclude access pseudoaneurysms. Patients were evaluated
at 2 and 6 months to assess for graft patency, access or outﬂow stenosis, endoleak, or stent graft migration.
Results: No procedural complications resulted from these interventions. An average of 1.8 endografts was placed per
patient, with patients requiring between 1 and 3 endografts to exclude pseudoaneurysms. Primary-assisted patency was
83% at completed 2-month follow-up and 54% at 6-month follow-up. At 12 months, primary-assisted patency was 50%.
Eleven patients left the study before 6-month follow-up: ﬁve (21%) required explantation secondary to infection between
1 and 4 months; three (13%) were lost to follow-up; two (8%) died of unrelated causes; and 1 requested explantation
citing pain from the “stent poking the vein.” Mean time to explantation secondary to infection was 2.4 months. Mean
duration of patency was 17.6 months with a range from 0 to 76 months. Mean duration of patency for patients who
completed 6-month follow-up was 28.7 months. The longest duration of patency is 6 years 4 months, after stent fracture
and subsequent placement of a new stent at 6 years 2 months. One other incident of stent fracture occurred at 36 months.
Dialysis patterns were not interrupted in either patient.
Conclusions: The long-term results demonstrate that endograft salvage of failing hemodialysis accesses is a viable and safe
alternative to open surgical revision that excludes pseudoaneurysms while maintaining uninterrupted access patency. A
larger sample size and longer follow-up are needed to support the study data. (J Vasc Surg 2013;57:137-43.)The incidence of end-stage renal disease has been
rising over the last two decades. In 2009, nearly 370,000
people were on hemodialysis (HD), with approximately
106,000 new patients being added annually.1 Medical
advances, in conjunction with implementation of the
National Kidney Foundation’s Kidney Disease Outcomes
Quality Initiative (KDOQI) in 1997, have led to an older
HD population as well as longer life expectancies after the
initiation of HD. This latter factdcoupled with a high
prevalence of central venous stenoses, which often are
the result of central venous catheter (CVC) placement
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://dx.doi.org/10.1016/j.jvs.2012.07.026functioning HD access. According to the Renal Physicians
Association (RPA), approximately 82% of patients initiate
HD with a CVC.2 The RPA has launched the Vascular
Access Initiative (VAI), a collaborative effort aimed at
lowering the rate of CVC-initiated HD as well as 90-day
catheter rates, in an effort to decrease CVC-associated
complications, including central venous stenoses. We
applaud this initiative; however, in the interim, regardless
of how HD was initiated, access complications must be
addressed and treated in order to maintain access patency
and functionality.
Dialysis access procedures and access complications are
the leading causes of morbidity among HD patients, often
resulting in an increased number of hospitalizations and
missed dialysis sessions. These complications burden the
health care system and disrupt patient care. As such,
limiting these complications can signiﬁcantly improve the
quality of life of dialysis patients while decreasing health
care costs. Complications of HD access include, but are
not limited to, erosions, infections, thrombosis, and pseu-
doaneurysms (PSAs). The PSAs form secondary to
repeated punctures that cause trauma to the vein or graft
with resultant dilatation. These often form in the setting
of high pressure secondary to arteriovenous ﬁstula (AVF)
or arteriovenous graft (AVG) outﬂow stenosis. Sullivan
et al3 reported that a stenosis >40% is associated with a
statistically signiﬁcant rise in graft pressure, which predisposes137
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PSAs can lead to skin erosion and eventual access infection
or PSA rupture. Currently, open surgical revision is the
standard of treatment for PSA repair. However, this
approach results in interruption of dialysis patterns and
may necessitate placement of a temporary CVC.
Although we agree that closure of the access by ligation
or excision and creation of a new access may be the simplest
method of excluding PSAs, it requires placement of
a temporary CVC and thus should be used only as a last
resort or in emergency situations.4 We hypothesize that
percutaneous covered stent, or endograft, placement is
a viable and safe alternative to open surgical revision of
PSAs that maintains uninterrupted patency and availability
of the access.
METHODS
Participants were prospectively offered enrollment in
the trial based upon clinical and ultrasonographic evalua-
tion of their HD accesses. From July 2005 to October
2009, 32 patients were prospectively evaluated; of these
patients, 24 were actively enrolled in the study. Eight
patients were excluded when they were found to have
unsatisfactory landing and seal zones upon evaluation. Of
the 24 patients included in the study, 20 had prosthetic
AVGs and four had autogenous AVFs. Although ﬁstulas
may dilate over time and become aneurysmal in size,
discrete PSAs arise more often in the setting of AVGs.
The four AVFs that were included in this study had focal
PSAs and were not diffusely aneurysmal. Generalized aneu-
rysmal dilatation would have resulted in exclusion from the
study secondary to inadequate landing zones.
Inclusion criteria included age older than 18 years,
ability to give informed consent, ample landing and seal
zones, life expectancy of at least 6 months (based on clin-
ical judgment), and absence of clinical signs of infection at
the PSA site. Exclusion criteria included pregnancy, age
younger than 18 years, inability to give informed consent,
insufﬁcient landing and seal zones, life expectancy less than
6 months, and active signs of infection surrounding the
PSA. Based on the surgeon’s discretion, a sufﬁcient landing
zone was deﬁned as being at least 1 cm on either end of the
endograft. Approval to conduct the study was obtained
from the Institutional Review Board of McLaren Flint
(Flint, Mich).
All procedureswere performedby a vascular surgeonwith
training in endovascular techniques. All 24 study patients
underwent duplex ultrasound scanning at an Intersocietal
Commission for the Accreditation of Vascular Laboratories
(ICAVL)-approved vascular laboratory before endograft
placement to evaluate inﬂow and outﬂow as well as the ﬁstula
or graft itself. Procedures were performed in an angiography
suite with patients under local anesthesia with or without
conscious sedation.Patientsweregiven aprophylactic intrave-
nous ﬁrst-generation cephalosporin or intravenous vancomy-
cin in the case of cephalosporin allergy. The access was
routinely cannulated using a 4F Micropuncture Introducer
Set (Cook Medical, Bloomington, Ind) through whichevaluation of arterial and venous outﬂow, diagnostic ﬁstulog-
raphy, and central venographywere performed.Heparin anti-
coagulationwasgiven at the surgeon’s discretion.Appropriate
endograft sizewas determined by using intraoperative ﬁstulo-
gram and accounting for 10% oversizing. Fluency self-
expanding nitinol stents (Bard Peripheral Vascular, Tempe,
Ariz) encapsulated in polytetraﬂuoroethylene were deployed
using a bareback technique, and a 6F sheath was placed after
the stent graft delivery catheter was removed. Angioplasty of
the deployed stent graft was routinely performed to ensure
full expansion of the endograft and to secure ﬁxation of the
seal zone aswell as the junctionsbetweenoverlying endografts
in order to prevent leakage. Adjunctive angioplasty was
performed as indicated to correct inﬂow or outﬂow stenoses.
Completion ﬁstulography was then performed. Fluoroscopy-
guided aspiration of the PSA sac was performed after stent
deployment and expansion. A pressure dressing was placed
over the stented segments at the surgeon’s discretion.Dialysis,
including that of the stented segment, was allowed to resume
immediately after endograft placement.
Follow-up at 2 and 6 months included clinical assess-
ment of access function as well as duplex ultrasound assess-
ment for graft patency, access or outﬂow stenosis,
endoleak, or stent graft migration. Study end points were
6-month duplex scan assessment, access thrombosis with
loss of access, access infection necessitating endograft
removal, or patient death.
RESULTS
Twenty-four patients underwent percutaneous endo-
graft placement between July 2005 and October 2009
(Table I). Seventeen patients were female, and seven
were male. There were 17 African American patients, six
Caucasian patients, and one Hispanic patient. Average
patient age at the time of endograft placement was
61.4 years. Twelve patients had a single PSA, and 12
patients had multiple PSAs. Nine patients (38%) were
treated with a single endograft, 11 patients (46%) required
two discontinuous devices, and four patients (17%)
required three stent grafts to exclude their PSAs. An
average of 1.8 stent grafts was placed per patient. Endo-
grafts ranged from 7 to 10 mm in diameter, with 8-mm 
>60-mm and 9-mm  60-mm grafts being the most
commonly used devices. No procedural complications
occurred as a result of the interventions.
Twenty patients (83%) had previously undergone
angioplasty of inﬂow or outﬂow stenosis (Table II). Two
had a history of percutaneous AVG thrombectomy before
stent graft placement. Adjunctive angioplasty was required
in 17 patients (71%) at the time of covered stent place-
ment. Of these patients, nine (53%) required adjunctive
angioplasty of outﬂow stenoses, seven (41%) required
angioplasty at the covered stent site, and one required
angioplasty of both outﬂow stenosis and the stent site.
Twenty patients (83%) had PSAs of a prosthetic AVG. Of
these patients, 13 (65%) were brachial artery to axillary
vein bridge grafts, ﬁve (25%) were axillary loop grafts,
one was a forearm loop graft, and one was a femoral
Table II. Procedure characteristics
Angioplasty
Previous 20/24 (83.3%)
Adjunctive 17/24 (70.8%)
Outﬂow stenosis 9/17 (52.9%)
Stent graft 7/17 (41.2%)
Both 1/17 (5.9%)
Prior thrombectomy 2/24 (8.3%)
Prosthetic arteriovenous grafts 20/24 (83.3%)
Brach-ax 13/20 (65.0%)
Axillary loop 5/20 (25.0%)
Forearm loop 1/20 (5.0%)
Femoral loop 1/20 (5.0%)
Arteriovenous ﬁstula 4/24 (16.7%)
Single pseudoaneurysm 12/24 (50.0%)
Multiple pseudoaneurysms 12/24 (50.0%)
Grafts per patient 1.8
1 9/24 (37.5%)
2 11/24 (45.8%)
3 4/24 (16.7%)
Procedural complications 0/24 (0.0%)
Brach-ax, Brachial artery to axillary vein bridge graft.
Table I. Patient characteristics
Case No. Race Age, years Gender Procedure date Access type Stent size, mm
1 H 46 F 07/15/2005 Axillary loop graft 9  60
2 B 48 F 10/12/2005 Brach-ax graft 9  60, 9  80, 10  40
3 B 65 F 10/28/2005 Brach-ax graft 10  60
4 B 60 F 12/01/2005 Brach-ax graft 9  40, 9  40
5 C 67 M 01/20/2006 Brach-cephalic ﬁstula 9  60
6 B 62 M 07/07/2006 Brach-cephalic ﬁstula 9  60, 10  80
7 B 60 M 07/18/2006 Brach-ax graft 10  40, 10  60, 10  80
8 C 65 F 11/29/2006 Axillary loop graft 8  80
9 B 64 F 01/26/2007 Axillary loop graft 9  60, 10  40
10 C 72 F 03/09/2007 Femoral loop graft 9  60, 9  60
11 B 62 M 04/11/2007 Brach-ax graft 10  60
12 C 79 F 09/14/2007 Axillary loop graft 8  80
13 B 66 F 10/19/2007 Brach-ax graft 8  40, 8  60
14 B 72 F 01/11/2008 Brach-ax graft 8  10
15 B 42 M 02/28/2008 Brach-ax graft 8  60
16 B 68 M 04/02/2008 Brach-ax graft 8  60, 8  60
17 B 70 F 05/30/2008 Brach-ax graft 9  80
18 B 85 F 06/11/2008 Brach-ax graft 7  40, 7  40, 8  60
19 B 77 F 10/08/2008 Brach-ax graft 9  80, 9  80
20 B 24 F 10/24/2008 Axillary loop graft 8  60, 8  60
21 C 65 F 11/05/2008 Brach-cephalic ﬁstula 10  60, 10  80, 10  80
22 B 39 F 06/01/2009 Brach-cephalic composite 7  60, 7  80
23 B 62 F 06/03/2009 Brach-ax graft 8  60, 9  80
24 C 53 M 10/28/2009 Forearm loop graft 9  40, 9  60
B, Black; Brach-ax, brachial artery to axillary vein bridge graft; Brach-cephalic, brachial artery to cephalic vein ﬁstula; C, Caucasian; F, female; H, Hispanic;
M, male.
Table III. Explantation and discontinuation of follow-up
Explantation þ discontinuation of follow-up 11/24 (45.8%)
Infection 5/24 (20.8%)
Lost to follow-up 3/24 (12.5%)
Death 2/24 (8.3%)
Patient request 1/24 (4.2%)
Mean time to explantation secondary to infection
(range), months
2.4 (1e4)
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skin or ulceration of the access, and one patient had
a ruptured PSA of an axillary loop graft. One patient
required percutaneous thrombectomy of his access at 1
and 3 months after stent graft exclusion of his PSAs.
Completed 2- and 6-month duplex scans showed
83% and 54% primary-assisted patency and effective exclu-
sion of PSAs, respectively. Primary-assisted patency wasdeﬁned as patency that required subsequent intervention
after endograft placement in order to maintain patency
but did not involve interruption of the dialysis regimen
or avoidance of the access.
Twenty of the 24 patients (83%) enrolled in the study
completed 2-month follow-up and demonstrated clinical
success and duplex-derived patency. Four patients did not
present for 2-month follow-up (Table III). Three patients
required endograft explantation before the 2-month
follow-up secondary to infection. All three of the infected
grafts were patent at the time of explantation. One patient
was lost to follow-up. Between endograft placement and
the initial 2-month follow-up, the probability of endograft
survival was 0.91 6 0.06 (Fig 1).
Thirteen patients completed 6-month follow-up for
a clinical success and duplex-derived patency of 54%.
Between 2 and 6 months, two additional patients required
explantation for infection (both at 4 months), two patients
died of unrelated causes, two more patients were lost to
Fig 1. Survival curve of 24 patients undergoing percutan-
eous endograft placement for repair of hemodialysis access
pseudoaneurysms.
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citing pain from the stent “poking the vein.” The two
grafts removed secondary to infection were patent at the
time of explantation, as was the graft removed per patient
request. The two patients who died of unrelated causes
also had grafts that remained patent at the time of their
deaths. One patient who was lost to follow-up subse-
quently presented for follow-up at 13 months and was
found to have access that was still patent. The probability
of endograft survival was found to be 0.71 6 0.10 between
4 and 6 months.
Retrospective review of patient charts showed that 11
patients who completed the 6-month follow-up had
endografts that were still patent at 12 months. One addi-
tional patient was found to have a patent access at 12
months. This patient had previously been lost to follow-
up but presented at 13 months with a patent, functioning
endograft. Thus, 12 of the 24 study patients (50%)
achieved primary or primary-assisted patency at 12 months.
Survival probability was 0.71 6 0.10 at 2-month intervals
between 6 and 12 months.
The mean duration of patency after PSA exclusion
and percutaneous covered stent placement was 17.6
months. To date, the longest duration of patency is
6 years 4 months, following stent fracture and subse-
quent repair with a 9-mm  50-mm ﬂared stent at 6
years 2 months (Fig 2). For the 13 patients who
completed 6-month follow-up and the one patient
who was lost to follow-up at 6 months but was later
found to have a patent access when she presented forfollow-up at 13 months, the mean duration of patency
was 28.7 months. One patient had access that remained
patent until she received a kidney transplant 12 months
after endograft placement.DISCUSSION
AVF or AVG PSAs complicate 2% to 10% of HD
accesses.5-7 These PSAs can be painful, may thrombose,
or may cause thinning of the skin leading to erosion.
Erosions eventually may result in PSA rupture with loss
of the access and a signiﬁcant risk of mortality. The stan-
dard approach to PSAs or erosions that threaten dialysis
access is open surgical revision with prosthetic graft
interposition bypass and exclusion of the PSA. Double
ligation and sacriﬁce of the access occasionally are neces-
sary, and temporary catheter placement frequently is
required.8
Although open surgical revision certainly has a role in
the treatment of complex PSAs, the results of our study
suggest that less complicated PSAs can be excluded with
minimally invasive endograft placement. Although all
PSAs can be excluded using open technique, not all are
candidates for endovascular repair. More complicated
PSAs that require open revision include those that are
diffusely aneurysmal, those without sufﬁcient landing
zones, and those complicated by overlying cutaneous infec-
tion. For patients who are candidates for endovascular
intervention, the advantages are obvious: less operative
time and risk, minimal blood loss, lower risk of wound
complications, and less patient discomfort. Indeed, endo-
vascular PSA repair usually can be performed in the outpa-
tient setting, as was the case for the majority of patients in
our study. Most importantly, HD patterns rarely need to
be disrupted, and catheter use, with its associated compli-
cations, can be avoided.
Our series showed that of the 20 patients who
completed 2-month follow-up duplex scanning and the
13 patients who completed 6-month follow-up duplex
scanning, all had primary-assisted patency of the treated
HD accesses. The patency of prior case series has ranged
from 20% to 100% of patients evaluated at 6 months.9e14
Shemesh et al4 reported functional patency in 87% of
patients at 12 months. We demonstrated similar results in
our study, with 92% primary-assisted patency at 12 months
among the 12 surviving patients who were patent at 6-
month follow-up and the one patient who presented for
late follow-up at 13 months. Patency is reduced to 50%
when all patients are accounted for, including those who
did not complete follow-up, those who died of unrelated
causes, and the patient whose access was removed after
kidney transplantation. In our experience, patients whose
access remained patent at 6 months had an excellent
chance of long-term patency.
One threat to long-term patency is recurrence of
outﬂow stenoses. Although adjunctive angioplasty of exist-
ing stenoses was performed at the time of endograft place-
ment, recurrence of these lesions was not noted because
Fig 2. A, Stent fracture. B, Pseudoaneurysm. C, After repair with endograft.
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plasty of incidentally encountered venous stenoses was per-
formed concurrently with endograft placement to improve
patient outcome but was not the primary reason for
intervention.
Endovascular treatment of PSAs is not a new concept.
Multiple authors have reported small case series ranging
from 2 to 20 patients.4,9-13 Previous series have reported
handmade endografts built upon balloon-expandable
stents and, more recently, self-expanding covered stents
such as the Wallgraft (Boston Scientiﬁc, Natick, Mass) or
the Viabahn (W. L. Gore & Associates, Flagstaff, Ariz).
Although none of the commercially available covered
stents are approved by the US Food and Drug Administra-
tion for this indication, the Fluency device (Bard Peripheral
Vascular, Tempe, Ariz) has several favorable attributes for
use in AVFs and AVGs. The stent pattern of this device
facilitates cannulation because it has larger interstices
between struts than either the Wallgraft or the Viabahn
device. The Fluency device also accommodates diameter
mismatches well without encroachment upon the smaller
vessel lumen, and it is ﬂexible enough to seal along curved
access segments, including looped grafts. This device was
chosen solely for these attributes, and no relationship exists
between the authors and Bard Peripheral Vascular. Ideally,
a larger study would be conducted in which patients were
stratiﬁed into one of three groups based on device manu-
facturer and outcomes are compared with those for open
surgical revision.
Because these devices are not engineered to withstand
repeated punctures with large-bore needles, durability has
been a primary concern for this procedure. Indeed, a prior
case report noted material failure leading to a recurrent
PSA in a Wallgraft-treated access.12 Vesely14 reported
one stent fracture in a series of 11 patients treated with
Viabahn-covered stents. In this study, we noted two late
complications of stent fracture with new PSA formation,
one at 36 months and one at 74 months, both of which
required placement of a new stent to maintain primary-
assisted patency of the access. However, dialysis patterns
were not interrupted in either case.Temporarily avoiding cannulation of the stented site
after endograft placement is intended to prevent damage
to the endograft as well as infectious complications associ-
ated with puncture of an aspirated PSA sac. Early in our
study, one stent graft was “crimped” by cannulation at
its end, which necessitated percutaneous angioplasty for
access salvage. Subsequently, we began marking the skin
overlying the center of each endograft to indicate where
cannulation should take place until involution of the
aspirated PSA sac made this apparent. Also, we aspirated
the PSA sac after endograft deployment to allow the
overlying skin to collapse and facilitate palpation and
subsequent cannulation of the access. Although some
surgeons do not advocate immediate access of stented
segments, we allowed and encouraged immediate resump-
tion of dialysis, including that of the stented segments.
Even PSAs with tenuous overlying skin can be cannulated
immediately after endograft placement as long as the over-
lying skin is intact. We were not made aware of any
dialysis-related complications from immediate access of
the newly implanted stent grafts, such as hematoma or
bleeding from the access site. We strongly believe that to
consider endovascular stent placement a viable option
for repair of access PSAs, early cannulation of the access
after endograft placement is essential.15 Any duration of
access unavailability obviates the beneﬁts of endovascular
versus open surgical repair.
Kim et al16 found that treating a prosthetic AVG PSA
with a covered stent was associated with the greatest risk of
subsequent AVG infection. A statistically signiﬁcant differ-
ence in infection rates was found between intragraft
covered stent placement for PSA exclusion (42%) versus
intragraft covered stent placement for any other indication
(18%; P ¼ .011).16 In our study, ﬁve accesses (21%) had to
be removed because of infection between 1 and 4 months
after deployment of the covered stent; two were AVFs, and
three were AVGs. None of the accesses were found to be
salvageable by open surgical revision, and all ﬁve were
excised. Whether an access can be salvaged by a short-
segment open surgical revision can only be determined at
the time of open surgical exploration. However, at that
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opportunity for endovascular repair lost.
In our study, median time to explantation secondary to
infection was 2 months (mean 2.4 months). Kim et al16 re-
ported a median time of 8.9 months from endograft place-
ment to explantation secondary to infection. Although
infection and subsequent explantation occurred earlier in
our study, the incidence of infections requiring explanta-
tion in our study was lower (21% vs 42%). In our study,
all ﬁve cases of infection occurred within the ﬁrst 4 months
of endograft placement. We attribute our earlier mean time
to infection and subsequent endograft removal to our
allowing immediate resumption of dialysis even if it
involved cannulation of the stented segment. We found
that, despite an increased incidence of early infections,
patients who had not developed an infection within the ﬁrst
4 months were likely to have accesses that remained patent
and free of infection in the long term.
Infections mostly likely represent contamination due to
repeated cannulation, although the possibility of an indo-
lent infection from implantation of the stent graft cannot
be excluded. Aside from repeated cannulations, multiple
factors may contribute to the etiology of endograft infec-
tion, including personal hygiene of the patient, obesity,
diabetes, age of the access, and deviation from sterile tech-
nique during dialysis.17 Although factors such as personal
hygiene, obesity, and diabetes were not directly noted in
our study, we observed that these issues are prevalent
within the patient population, and it is quite likely that at
least one, if not all, of these factors played a role in the
development of infections in the study patients. Age of
the access was not noted in this study because we did not
create the accesses in all of the study patients. We are
also unable to comment on sterility during dialysis because
dialysis occurred at outside facilities not under our direct
supervision. Despite strict adherence to sterile HD tech-
nique, dialysis patients are at a signiﬁcantly higher risk for
invasive infections than the general population.18 In an
attempt to reduce the likelihood of postsurgical infection
in our study, patients with any clinical evidence of PSA
infection or cellulitis surrounding an erosion were excluded
from the study. Eight patients presented with tenuous skin
or ulceration overlying the PSA, and one patient presented
with a frankly ruptured PSA. However, of these nine
patients, only one required explantation secondary to infec-
tion. A clear causative relationship between compromised
skin and eventual development of infection and subsequent
explantation was not established. In addition to these
precautions, we administered perioperative prophylactic
antibiotics during endograft placement. Prophylaxis was
not administered in the study by Kim et al,16 which may
have contributed to their higher rate of postoperative graft
infections.
Citing the risk of infections, Kim et al16 suggest that
perhaps endograft exclusion of PSAs should be avoided
altogether. We strongly disagree, as our long-term results
demonstrate that this minimally invasive endovascular tech-
nique effectively excludes PSAs while it prolongs the use offailing HD access and avoids the risks associated with open
surgical revision.19
CONCLUSIONS
Hemodialysis patients constitute a growing portion of
vascular surgery practices. Currently, no formal practice
guidelines are in place regarding the use of endografts to
exclude PSAs and prolong access lifespan in dialysis
patients. Although we found endograft salvage to be
a viable option, a larger sample size and longer follow-up
are needed to validate and support these initial observa-
tions. The results of our study suggest that a direct compar-
ison between endovascular and open surgical methods to
manage HD access PSAs and erosions should be initiated
in an effort to identify best practices for management of
PSA exclusion and salvage of failing HD access.AUTHOR CONTRIBUTIONS
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